Physician profile
Samuel Hanon
NPI 1962519892
$28,270.19
in general payments reported to CMS, 2019-2025
12 companies · $1,505 in 2025
The $1,505 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $1,409 · 2021: $1,657 · 2022: $1,571 · 2023: $2,664 · 2024: $1,279 · 2025: $1,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,499 · Travel and Lodging: $949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,499.18 |
| Travel and Lodging | $948.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $13,738.73 | 2019-2021 | |
| Boston Scientific Corporation | $12,965.00 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd, General - Therapies |
| Medtronic, INC. | $1,121.44 | 2023 | Micra, Linq II |
| Abbott Laboratories | $150.20 | 2021 | |
| Novartis Pharmaceuticals Corporation | $131.80 | 2019-2022 | |
| Atricure, INC. | $30.49 | 2024 | |
| Pfizer INC. | $28.45 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.91 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $23.86 | 2021 | |
| Merck Sharp & Dohme LLC | $18.42 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.36 | 2021 | |
| Ge Healthcare | $16.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Hanon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.